BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2282987)

  • 1. A formalin inactivated whole SIV vaccine and a glycoprotein-enriched subunit vaccine confers protection against experimental challenge with pathogenic live SIV in rhesus monkeys.
    Murphey-Corb M; Martin LN; Davison-Fairburn B; Montelaro RC; Miller M; West M; Ohkawa S; Baskin GB; Zhang JY; Putney S
    Dev Biol Stand; 1990; 72():273-85. PubMed ID: 2282987
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV.
    Marthas ML; Miller CJ; Sutjipto S; Higgins J; Torten J; Lohman BL; Unger RE; Ramos RA; Kiyono H; McGhee JR
    J Med Primatol; 1992; 21(2-3):99-107. PubMed ID: 1433273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge.
    Putkonen P; Thorstensson R; Cranage M; Nilsson C; Ghavamzadeh L; Albert J; Greenaway P; Biberfeld G
    J Med Primatol; 1992; 21(2-3):108-12. PubMed ID: 1433260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines.
    Heeney JL; de Vries P; Dubbes R; Koornstra W; Niphuis H; ten Haaft P; Boes J; Dings ME; Morein B; Osterhaus AD
    J Med Primatol; 1992; 21(2-3):126-30. PubMed ID: 1433263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIV vaccine protection of rhesus monkeys.
    Gardner MB; Carlson JR; Jennings M; Rosenthal A; Langlois A; Haynes B; Bolognesi D; Palker TJ
    Biotechnol Ther; 1991; 2(1-2):9-19. PubMed ID: 1845125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
    Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
    J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys.
    Murphey-Corb M; Montelaro RC; Miller MA; West M; Martin LN; Davison-Fairburn B; Ohkawa S; Baskin GB; Zhang JY; Miller GB
    AIDS; 1991 Jun; 5(6):655-62. PubMed ID: 1883540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of Macaca fascicularis with inactivated SIV preparations: challenge with human- or monkey-derived SIV and the effects of a longer immunization schedule.
    Titti F; Koanga Mogtomo ML; Borsetti A; Geraci A; Sernicola L; Panzini G; Turillazzi GP; Baroncelli S; Giovannetti A; Zamarchi R
    J Med Primatol; 1993; 22(2-3):110-8. PubMed ID: 8411103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIV infection of macaques: a model for AIDS vaccine development.
    Gardner MB
    Dev Biol Stand; 1990; 72():259-66. PubMed ID: 2178124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of pregnant cynomolgus monkeys with whole formalin-inactivated SIVmac251.
    Titti F; Borsetti A; Geraci A; Sernicola L; Giuseppini L; Turillazzi GP; Pace M; Baroncelli S; Amadori A; Giovannetti A
    J Med Primatol; 1992; 21(2-3):91-8. PubMed ID: 1433272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge.
    Osterhaus A; de Vries P; Morein B; Akerblom L; Heeney J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1507-10. PubMed ID: 1466991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
    Carlson JR; McGraw TP; Keddie E; Yee JL; Rosenthal A; Langlois AJ; Dickover R; Donovan R; Luciw PA; Jennings MB
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1239-46. PubMed ID: 2078406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
    Nixon DF; Donahoe SM; Kakimoto WM; Samuel RV; Metzner KJ; Gettie A; Hanke T; Marx PA; Connor RI
    Virology; 2000 Jan; 266(1):203-10. PubMed ID: 10612675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A formalin-inactivated whole SIV vaccine confers protection in macaques.
    Murphey-Corb M; Martin LN; Davison-Fairburn B; Montelaro RC; Miller M; West M; Ohkawa S; Baskin GB; Zhang JY; Putney SD
    Science; 1989 Dec; 246(4935):1293-7. PubMed ID: 2555923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable.
    Murphey-Corb M; Ohkawa S; Davison-Fairburn B; Martin LN; Baskin GB; Langlois AJ; McIntee M; Narayan O; Gardner MB
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1475-8. PubMed ID: 1466986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.